Literature DB >> 25667271

Making progress on progression in metastatic prostate cancer.

Andrew J Armstrong1, Susan Halabi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25667271     DOI： 10.1200/JCO.2014.59.4283

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.

Authors:  Stephanie A Harmon; Ethan Bergvall; Esther Mena; Joanna H Shih; Stephen Adler; Yolanda McKinney; Sherif Mehralivand; Deborah E Citrin; Anna Couvillon; Ravi A Madan; James L Gulley; Ronnie C Mease; Paula M Jacobs; Martin G Pomper; Baris Turkbey; Peter L Choyke; M Liza Lindenberg
Journal:  J Nucl Med       Date:  2018-03-30       Impact factor: 10.057

2.  Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate: An evidence-based case report and review of literature.

Authors:  Oliver E Yausep; Raksheeth Agarwal; Rifqha Aulina; Anthony E Wijaya; Ilonka Amaia; Addina W Moekti; Ikhwan Rinaldi; Agus Rizal A H Hamid
Journal:  Clin Case Rep       Date:  2019-07-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.